Partnervest Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Partnervest Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-89	Closed	-$8K	–	786
2014 Q2	$8K	Hold	89	–	–	﹤0.01%	738
2014 Q1	$6K	Hold	89	–	–	﹤0.01%	776
2013 Q4	$7K	Hold	89	–	–	﹤0.01%	717
2013 Q3	$7K	Hold	89	–	–	﹤0.01%	727
2013 Q2	$7K	Buy	+89	New	+$6.55K	﹤0.01%	675

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Partnervest Advisory Services's VRTX Position: Q3 2014 in Review

Partnervest Advisory Services sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 89 shares — an estimated $8K sold.

Partnervest Advisory Services first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $8K in Q2 2014. 431 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

Partnervest Advisory Services reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Partnervest Advisory Services sold 89 Vertex Pharmaceuticals shares in Q3 2014, an estimated $8K.
Partnervest Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Partnervest Advisory Services's Vertex Pharmaceuticals position peaked at $8K in Q2 2014.
431 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on Partnervest Advisory Services's 13F filing for Q3 2014, filed 7 Nov 2014.